A 20-patient, single-site U.S. pilot has begun enrolling at Johns Hopkins under an FDA IDE to evaluate the safety and tolerability of Comphya’s CaverSTIM, an implantable neuromodulation system placed during robotic-assisted radical prostatectomy in men aged 30–75 with normal preoperative erectile function. The first patient has been implanted, with early patient satisfaction and effectiveness signals planned as secondary observations.
The core development is a perioperative neurostimulation approach to post-prostatectomy erectile dysfunction, delivering subsensory electrical stimulation to the cavernous nerves starting one week after surgery via a subcutaneously implanted pulse generator and pelvic electrode array. The protocol targets a well-defined, high-incidence complication where recovery typically stretches months to years and remains incomplete in many cases. Unlike salvage interventions or pharmacologic rehabilitation, CaverSTIM is designed to be implanted at the index procedure and programmed postoperatively, positioning it squarely in the surgical workflow.
Strategically, this is an expansion play into the perioperative preservation space for sexual function, aiming to move upstream from the refractory ED cohort into prevention and recovery. The bet is that continuous, targeted stimulation can support nerve recovery following surgical insult, potentially reducing reliance on PDE5 inhibitors, vacuum devices, injections, or later-stage prostheses. It also aligns with broader device trends in urology toward nerve-focused modulation rather than purely mechanical solutions. The tension is twofold: demonstrating a clear, causally attributable benefit beyond natural recovery trajectories, and proving that an additional implantable system at the time of cancer surgery can be justified by risk, cost, and workflow in a setting already under operating room time and staffing pressure.
For sites, this model requires tight coordination between oncology/urology teams and device programming staff, new perioperative training, and robust patient-reported outcome capture over extended follow-up. Screening is nontrivial: candidates must have intact baseline erectile function, undergo robotic radical prostatectomy at a center willing to incorporate the implant, and commit to device programming and adherence visits. CROs and device trial operators will contend with surgical scheduling variability, standardized surgical technique documentation, and the need to control for nerve-sparing variability that can confound endpoints. Regulators will be evaluating first-of-kind neuromodulation for ED recovery; longer term, this likely sets up a PMA-like evidentiary bar with durable functional outcomes, safety, and device reliability. Payers and hospital value committees will look for clear improvements in time to recovery and rates of spontaneous function without ongoing adjuncts, alongside acceptable infection, explant, and lead-related event rates.
Next, watch for feasibility outcomes that go beyond uneventful implantation: device-related adverse events, programming adherence, explant rates, and early signals on IIEF-EF domain changes, erection hardness, or time to unassisted intercourse. If this pilot confirms procedural practicality and an acceptable safety profile, the pivotal question becomes trial design. A multicenter randomized study will need to address controls—sham neuromodulation carries ethical and logistical complexity—standardize nerve-sparing documentation, and fix clear, regulator-aligned endpoints over 6–12 months. Operationally, adoption will hinge on surgical time impact, ease of electrode placement, recharge burden, and whether programming can be embedded within routine post-op pathways. The upside is a potentially new category in post-prostatectomy rehabilitation; the risk is that incremental gains, or heterogeneity by surgical technique, blunt the value proposition. Expect signals on enrollment velocity, protocol amendments for parameter optimization, and early adverse event profiles to determine whether this strategy advances to a multicenter pivotal in the near term.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
